217 related articles for article (PubMed ID: 21463127)
41. Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells in vitro.
Calzavara E; Chiaramonte R; Cesana D; Basile A; Sherbet GV; Comi P
J Cell Biochem; 2008 Apr; 103(5):1405-12. PubMed ID: 17849443
[TBL] [Abstract][Full Text] [Related]
42. Use of antioxidant nanoliposomes for co-delivery of PTEN plasmids and plumbagin to induce apoptosis in hepatic cancer cells.
Bhagat S; Singh S
Biomed Mater; 2024 Feb; 19(2):. PubMed ID: 38215478
[TBL] [Abstract][Full Text] [Related]
43. PTEN loss correlates with T cell exclusion across human cancers.
Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
[TBL] [Abstract][Full Text] [Related]
44. Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways.
Wu KN; Zhao YM; He Y; Wang BS; Du KL; Fu S; Hu KM; Zhang LF; Liu LZ; Hu YX; Wang YJ; Huang H
Leuk Lymphoma; 2014 Mar; 55(3):668-76. PubMed ID: 23741975
[TBL] [Abstract][Full Text] [Related]
45. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
46. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
[TBL] [Abstract][Full Text] [Related]
47. CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia.
Cardoso BA; Duque M; Gírio A; Fragoso R; Oliveira ML; Allen JR; Martins LR; Correia NC; Silveira AB; Veloso A; Kimura S; Demoen L; Matthijssens F; Jeha S; Cheng C; Pui CH; Grosso AR; Neto JL; De Almeida SF; Van Vlieberghe P; Mullighan CG; Yunes JA; Langenau DM; Pflumio F; Barata JT
Haematologica; 2024 Jun; 109(6):1713-1725. PubMed ID: 38058200
[TBL] [Abstract][Full Text] [Related]
48. Suppression of leukemia development caused by PTEN loss.
Guo W; Schubbert S; Chen JY; Valamehr B; Mosessian S; Shi H; Dang NH; Garcia C; Theodoro MF; Varella-Garcia M; Wu H
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1409-14. PubMed ID: 21212363
[TBL] [Abstract][Full Text] [Related]
49. (‑)‑Epigallocatechin‑3‑gallate induces apoptosis in human pancreatic cancer cells via PTEN.
Liu S; Xu ZL; Sun L; Liu Y; Li CC; Li HM; Zhang W; Li CJ; Qin W
Mol Med Rep; 2016 Jul; 14(1):599-605. PubMed ID: 27176210
[TBL] [Abstract][Full Text] [Related]
50. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination.
Yu JS; Cui W
Development; 2016 Sep; 143(17):3050-60. PubMed ID: 27578176
[TBL] [Abstract][Full Text] [Related]
51. Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia.
Huang FF; Wu DS; Zhang L; Yu YH; Yuan XY; Li WJ; Chen XP; Zhao XL; Chen FP; Zeng H
Cancer Lett; 2013 Aug; 336(1):96-105. PubMed ID: 23603434
[TBL] [Abstract][Full Text] [Related]
52. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Gutierrez A; Sanda T; Grebliunaite R; Carracedo A; Salmena L; Ahn Y; Dahlberg S; Neuberg D; Moreau LA; Winter SS; Larson R; Zhang J; Protopopov A; Chin L; Pandolfi PP; Silverman LB; Hunger SP; Sallan SE; Look AT
Blood; 2009 Jul; 114(3):647-50. PubMed ID: 19458356
[TBL] [Abstract][Full Text] [Related]
53. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
[TBL] [Abstract][Full Text] [Related]
54. Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
Grzes KM; Swamy M; Hukelmann JL; Emslie E; Sinclair LV; Cantrell DA
Leukemia; 2017 Dec; 31(12):2771-2779. PubMed ID: 28546582
[TBL] [Abstract][Full Text] [Related]
55. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
56. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
[TBL] [Abstract][Full Text] [Related]
57. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
[TBL] [Abstract][Full Text] [Related]
58. Ursolic acid attenuates diabetic mesangial cell injury through the up-regulation of autophagy via miRNA-21/PTEN/Akt/mTOR suppression.
Lu X; Fan Q; Xu L; Li L; Yue Y; Xu Y; Su Y; Zhang D; Wang L
PLoS One; 2015; 10(2):e0117400. PubMed ID: 25689721
[TBL] [Abstract][Full Text] [Related]
59. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
60. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
